ALOX5 and prostate carcinoma: While ALOX5 inhibition triggers marked apoptosis in human prostate cancer cells [138], it is overexpressed in prostate adenocarcinoma, PDAC [139], hepatocellular carcinoma [140], and high-grade astrocytomas [141].